AGER and prostate carcinoma: Healey and co-researchers [139] at Swansea University, Wales Cancer Research Centre, developed new RAGE-targeted ADCs and demonstrated their efficacy against ovarian and prostate cancers, which significantly express RAGE, yet lack efficient targeted drugs to treat.